miR-21 Induces Chemoresistance in Ovarian Cancer Cells via Mediating the Expression and Interaction of CD44v6 and P-gp

References

• Zhang X-Y, Zhang P-Y. Recent perspectives of epithelial ovarian carcinoma. Oncol Lett. 2016;12(5):3055–3058. doi:10.3892/ol.2016.5107
   PubMed Web of Science ®Google Scholar
• Karimi-Zarchi M, Mortazavizadeh SM, Bashardust N, et al. The clinicopathologic characteristics and 5-year survival rate of epithelial ovarian cancer in Yazd, Iran. Electron Physician. 2015;7(6):1399–1406. doi:10.14661/1399
   PubMedGoogle Scholar
• Zhang X-Y, Zhang PY. Recent perspectives of epithelial ovarian carcinoma. Oncol Lett. 2020;20(5).
   Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30. doi:10.3322/caac.21442
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132. doi:10.3322/caac.21338
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29. doi:10.3322/caac.21254
   PubMed Web of Science ®Google Scholar
• Au Yeung CL, Co NN, Tsuruga T, et al. Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1. Nat Commun. 2016;7:11150. doi:10.1038/ncomms11150
   PubMed Web of Science ®Google Scholar
• Lloyd KL, Cree IA, Savage RS. Prediction of resistance to chemotherapy in ovarian cancer: a systematic review. BMC Cancer. 2015;15:117. doi:10.1186/s12885-015-1101-8
   PubMed Web of Science ®Google Scholar
• Cannistra SA. Cancer of the ovary. N Engl J Med. 2004;351(24):2519–2529. doi:10.1056/NEJMra041842
   PubMed Web of Science ®Google Scholar
• Liu LL, Lu SX, Li M, et al. FoxD3-regulated microRNA-137 suppresses tumour growth and metastasis in human hepatocellular carcinoma by targeting AKT2. Oncotarget. 2014;5(13):5113–5124. doi:10.18632/oncotarget.2089
   PubMedGoogle Scholar
• Yanaihara N, Caplen N, Bowman E, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 2006;9(3):189–198. doi:10.1016/j.ccr.2006.01.025
   PubMed Web of Science ®Google Scholar
• Fiannaca A, La Rosa M, La Paglia L, et al. Analysis of miRNA expression profiles in breast cancer using biclustering. BMC Bioinform. 2015;16(Suppl 4):S7. doi:10.1186/1471-2105-16-S4-S7
   PubMedGoogle Scholar
• Lee EJ, Gusev Y, Jiang J, et al. Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer. 2007;120(5):1046–1054. doi:10.1002/ijc.22394
   PubMed Web of Science ®Google Scholar
• Ruan K, Fang X, Ouyang G. MicroRNAs: novel regulators in the hallmarks of human cancer. Cancer Lett. 2009;285(2):116–126. doi:10.1016/j.canlet.2009.04.031
   PubMed Web of Science ®Google Scholar
• Vandghanooni S, Eskandani M, Montazeri V, et al. Survivin-deltaEx3: a novel biomarker for diagnosis of papillary thyroid carcinoma. J Cancer Res Ther. 2011;7(3):325–330. doi:10.4103/0973-1482.87038
   PubMed Web of Science ®Google Scholar
• Dong Z, Ren L, Lin L, et al. Effect of microRNA-21 on multidrug resistance reversal in A549/DDP human lung cancer cells. Mol Med Rep. 2015;11(1):682–690. doi:10.3892/mmr.2014.2662
   PubMed Web of Science ®Google Scholar
• Pink RC, Samuel P, Massa D, et al. The passenger strand, miR-21-3p, plays a role in mediating cisplatin resistance in ovarian cancer cells. Gynecol Oncol. 2015;137(1):143–151. doi:10.1016/j.ygyno.2014.12.042
   PubMed Web of Science ®Google Scholar
• Echevarria-Vargas IM, Valiyeva FandVivas-Mejia PE. Upregulation of miR-21 in cisplatin resistant ovarian cancer via JNK-1/c-Jun pathway. PLoS One. 2014;9(5):e97094. doi:10.1371/journal.pone.0097094
   PubMed Web of Science ®Google Scholar
• Yang H, Kong W, He L, et al. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res. 2008;68(2):425–433. doi:10.1158/0008-5472.CAN-07-2488
   PubMed Web of Science ®Google Scholar
• Xie Z, Cao L, Zhang J. miR-21 modulates paclitaxel sensitivity and hypoxia-inducible factor-1alpha expression in human ovarian cancer cells. Oncol Lett. 2013;6(3):795–800. doi:10.3892/ol.2013.1432
   PubMed Web of Science ®Google Scholar
• Morath I, Hartmann TN, Orian-Rousseau V. CD44: more than a mere stem cell marker. Int J Biochem Cell Biol. 2016;81(Pt A):166–173. doi:10.1016/j.biocel.2016.09.009
   PubMedGoogle Scholar
• Ravindranath AK, Kaur S, Wernyj RP, et al. CD44 promotes multi-drug resistance by protecting P-glycoprotein from FBXO21-mediated ubiquitination. Oncotarget. 2015;6(28):26308–26321. doi:10.18632/oncotarget.4763
   PubMedGoogle Scholar
• Miletti-Gonzalez KE, Chen S, Muthukumaran N, et al. The CD44 receptor interacts with P-glycoprotein to promote cell migration and invasion in cancer. Cancer Res. 2005;65(15):6660–6667. doi:10.1158/0008-5472.CAN-04-3478
   PubMed Web of Science ®Google Scholar
• Qin Y, Zhang Z, Huang C, et al. Folate-targeted redox-responsive polymersomes loaded with chemotherapeutic drugs and tariquidar to overcome drug resistance. J Biomed Nanotechnol. 2018;14(10):1705–1718. doi:10.1166/jbn.2018.2623
   PubMed Web of Science ®Google Scholar
• Baez-Vega PM, Echevarria Vargas IM, Valiyeva F, et al. Targeting miR-21-3p inhibits proliferation and invasion of ovarian cancer cells. Oncotarget. 2016;7(24):36321–36337. doi:10.18632/oncotarget.9216
   PubMedGoogle Scholar
• Chen Y, Chen Q, Liu Q, et al. Human epididymis protein 4 expression positively correlated with miR-21 and served as a prognostic indicator in ovarian cancer. Tumour Biol. 2016;37(6):8359–8365. doi:10.1007/s13277-015-4672-8
   PubMed Web of Science ®Google Scholar
• Feng YHandTsao Y-H, Tsao C-J. Emerging role of microRNA-21 in cancer. Biomed Rep. 2016;5(4):395–402. doi:10.3892/br.2016.747
   PubMedGoogle Scholar
• Bai H, Xu R, Cao Z, et al. Involvement of miR-21 in resistance to daunorubicin by regulating PTEN expression in the leukaemia K562 cell line. FEBS Lett. 2011;585(2):402–408. doi:10.1016/j.febslet.2010.12.027
   PubMed Web of Science ®Google Scholar
• Tomimaru Y, Eguchi H, Nagano H, et al. MicroRNA-21 induces resistance to the anti-tumour effect of interferon-alpha/5-fluorouracil in hepatocellular carcinoma cells. Br J Cancer. 2010;103(10):1617–1626. doi:10.1038/sj.bjc.6605958
   PubMed Web of Science ®Google Scholar
• Zhang HL, Si LB, Zeng A, et al. MicroRNA-21 antisense oligonucleotide improves the sensitivity of A375 human melanoma cell to Cisplatin: an in vitro study. J Cell Biochem. 2018;119(4):3129–3141. doi:10.1002/jcb.26455
   PubMed Web of Science ®Google Scholar
• El-Readi MZ, Eid S, Abdelghany AA, et al. Resveratrol mediated cancer cell apoptosis, and modulation of multidrug resistance proteins and metabolic enzymes. Phytomedicine. 2019;55:269–281. doi:10.1016/j.phymed.2018.06.046
   PubMed Web of Science ®Google Scholar
• Guo Q, Jing FJ, Qu HJ, et al. Ubenimex reverses MDR in gastric cancer cells by activating caspase-3-mediated apoptosis and suppressing the expression of membrane transport proteins. Biomed Res Int. 2019;2019:4390839. doi:10.1155/2019/4390839
   PubMed Web of Science ®Google Scholar
• Shi J, Zhou Z, Di W, Li N. Correlation of CD44v6 expression with ovarian cancer progression and recurrence. BMC Cancer. 2013,13:182. doi:10.1186/1471-2407-13-182
   Web of Science ®Google Scholar
• Hara T, Makino T, Yamasaki M, et al. Effect of c-Met and CD44v6 expression in resistance to chemotherapy in esophageal squamous cell carcinoma. Ann Surg Oncol. 2019;26(3):899–906. doi:10.1245/s10434-018-07126-5
   PubMed Web of Science ®Google Scholar
• Misra S, Ghatak S, Toole BP Regulation of MDR1 expression and drug resistance by a positive feedback loop involving hyaluronan, phosphoinositide 3-kinase, and ErbB2. J Biol Chem. 2005;280(21):20310–20315. doi:10.1074/jbc.M500737200
   PubMed Web of Science ®Google Scholar